NDC 65219-594 – Tyenne
Tocilizumab 400 mg/20mL · Injection, Solution, Concentrate · Intravenous
Product NDC65219-594
Product details
- Brand name
- Tyenne
- Generic name
- Tocilizumab-aazg
- Labeler
- Fresenius Kabi USA, LLC
- Dosage form
- Injection, Solution, Concentrate
- Route
- Intravenous
- Marketing category
- BLA · BLA761275
- Marketed since
- April 15, 2024
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-6 Receptor Antagonist
Active ingredients
- Tocilizumab 400 mg/20mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 65219-594-20 | 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-594-20) / 20 mL in 1 VIAL, SINGLE-DOSE | Apr 15, 2024 |
Recalls mentioning this NDC
- D-0827-2026 Sep 2, 2026 · Class I
Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
Other Tyenne products
- 65219-590 Tocilizumab 80 mg/4mL · Injection, Solution, Concentrate · Fresenius Kabi USA, LLC
- 65219-592 Tocilizumab 200 mg/10mL · Injection, Solution, Concentrate · Fresenius Kabi USA, LLC
- 65219-584 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-586 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-596 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC
- 65219-598 Tocilizumab 162 mg/.9mL · Injection, Solution · Fresenius Kabi USA, LLC